Current version snapshot

Not FDA-approved↗Safety records↗↗

Current · version 3: KPV↗

Related names recorded in this version: Lys-Pro-Val↗

A three-amino-acid peptide that is not FDA-approved. FDA’s 2026 review found no studies of KPV in people.↗

This immutable URL preserves the current public version.
The canonical profile remains the primary reading view. Read the canonical profile.
Update · November 14, 2026

We added a plain-language reader guide with cited answers, re-checked FDA’s KPV briefing, and added HHS’s October 30, 2026 draft enforcement-discretion policy, which lists KPV acetate. FDA has not issued a final 503A rule. 156

What this version reported

FDA staff recommended in May 2026 against adding KPV to the 503A compounding list, and FDA has not issued a final rule. An October 30, 2026 HHS draft enforcement-discretion policy lists KPV acetate among six peptides for which HHS says it does not intend to take enforcement action against licensed compounders who meet its conditions; it does not make KPV an FDA-approved drug.↗↗↗↗

Organizations named in cited records:
  • U.S. Food and Drug Administration↗↗
  • U.S. Department of Health and Human Services↗

Reader guide in this version

Key takeaway

KPV is a three-amino-acid peptide (lysine, proline and valine) related to a natural hormone, and the research on it comes from animal and laboratory studies.1 It is not an FDA-approved drug, and FDA’s 2026 evaluation found no product containing it authorized in the European Union.1 FDA found no studies of KPV in people at all, so its effects and safety in humans are unknown.1 FDA staff recommended against adding KPV to the list of substances pharmacies may use in compounding, but an October 2026 HHS draft policy lists it among six peptides for which HHS says it does not intend to take enforcement action against licensed compounders who meet its conditions while FDA’s rulemaking continues.1,5,6

At a glance

What it is
A peptide of three amino acids: lysine, proline and valine. Research FDA reviewed describes it as the end segment of alpha-melanocyte-stimulating hormone.1
FDA status
Not FDA-approved. FDA staff recommended in May 2026 against adding KPV to the 503A compounding list, and FDA has not issued a final rule. Under an October 30, 2026 HHS draft enforcement-discretion policy, KPV acetate is one of six listed peptides; HHS says it does not intend to take enforcement action against licensed pharmacies, federal facilities or physicians that compound it under the policy’s conditions.1,5,6
Human evidence
None found. FDA identified no clinical studies or other human exposure data for KPV.1
Evidence strength
Animal and lab studies only

What is KPV?

KPV is a small peptide made of three amino acids: lysine (K), proline (P) and valine (V). Research FDA reviewed describes it as the final three amino acids of alpha-melanocyte-stimulating hormone (α-MSH), a natural hormone with anti-inflammatory effects.1

FDA could not determine how long or how widely KPV has been used in compounding. Outsourcing facilities reported no products containing it from 2017 to June 2025.1

FDA found websites promoting KPV for inflammatory and gut conditions, wound healing and skin health, sometimes combined with other peptides such as BPC-157 and TB-500.1

How is KPV thought to work?

How KPV works has not been established. FDA’s briefing states that the molecular targets behind its reported effects remain unknown.1

Unlike the full hormone it comes from, KPV did not appear to act through the hormone’s usual melanocortin receptors in laboratory studies. Researchers have proposed that it may dampen inflammatory signaling inside cells instead.1

FDA found no pharmacokinetic studies showing how KPV is absorbed or handled by the body.1

What do human studies show?

There are none in FDA’s review. FDA evaluated KPV for wound healing and inflammatory conditions and found no clinical studies or other human exposure data for KPV by any route.1

The nine references submitted to FDA in support of KPV were animal studies of related hormone fragments and one laboratory study in donated human skin.1

FDA’s searches of its adverse-event databases through December 2025 found no reports involving KPV.1

FDA concluded that there is a lack of evidence to evaluate whether KPV works for the proposed uses and that its safety risks in people are unknown.1

What the evidence base contains

  • Animal or laboratory research Rodent and cell studies reporting anti-inflammatory and wound-healing effects. FDA notes that the molecular targets behind these effects remain unknown.1
  • Animal or laboratory research A laboratory study in donated human skin that found KPV does not pass well through the skin’s outer layer.1

Evidence-strength label: Animal and lab studies only. How this label is assigned

Is KPV FDA-approved?

No. FDA’s May 2026 evaluation states that neither KPV free base nor KPV acetate is a component of an FDA-approved drug and that there is no United States Pharmacopeia monograph for either.1

Under section 503A of the federal drug law, the list of bulk substances that pharmacies can use in compounding, known as the 503A bulks list, is being developed through FDA rulemaking.5

FDA staff evaluated both forms of KPV for that list for wound healing and inflammatory conditions and recommended against adding either. They cited poor chemical characterization, unknown extent of use, no human data on safety or effectiveness, and existing FDA-approved treatments.1

FDA’s compounding safety-risk page, last updated April 22, 2026, lists KPV among substances whose nominations were withdrawn and says FDA has not identified any human exposure data for it.3

HHS’s policy document states that KPV was in FDA’s Category 2, the group of nominated substances that may present significant safety risks, from September 2023 until April 22, 2026, and that neither change altered its status under section 503A.3,6

FDA’s Pharmacy Compounding Advisory Committee discussed KPV on July 23, 2026. HHS’s policy document states that the committee voted in favor of including it, while FDA’s drug-review center had recommended against listing either form. FDA’s own meeting page, last updated August 6, 2026, lists no vote record.1,2,6

On October 30, 2026, HHS published notice of a draft policy saying it does not intend to take enforcement action against licensed pharmacies, federal facilities or physicians compounding with the peptide substances listed in the policy’s appendix while the 503A list is developed. HHS calls it an interim policy, says it is not binding, and says it may be revisited if safety or quality problems arise.5,6

Appendix A of the policy lists six peptides: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. For KPV, the policy covers only the acetate salt form. It applies only when its conditions are met, including a patient-specific prescription, a single listed active ingredient, bulk substance from an FDA-registered facility with a certificate of analysis, and reporting of serious adverse events to FDA.6

HHS and FDA staff weigh the same record differently. HHS’s policy document says use of KPV is now documented, that newer test results for the acetate form supply what FDA staff found missing, and that FDA staff’s safety conclusion reflects an absence of information rather than an observed harm. FDA staff had found no human data at all.1,6

The policy does not make KPV an FDA-approved drug and is not an FDA rule. HHS notes that FDA does not review compounded drugs for safety, effectiveness or quality before they are marketed.5,6

Timeline

  1. In September 2023, KPV is placed in FDA’s Category 2 of nominated compounding substances that may present significant safety risks, according to HHS’s policy document.6
  2. A Federal Register notice announces the July advisory-committee meeting that will discuss KPV and opens a public comment docket.4
  3. KPV leaves Category 2, according to HHS’s policy document. FDA’s compounding safety-risk page, as last updated that day, lists it among withdrawn nominations.3,6
  4. FDA staff date their evaluation recommending that KPV not be added to the 503A bulks list.1
  5. FDA’s Pharmacy Compounding Advisory Committee discusses KPV.2
  6. HHS publishes notice of a draft enforcement-discretion policy whose Appendix A lists KPV among six peptide substances used in compounding.5,6

What is still unknown?

Whether KPV has any benefit in people: FDA found no human studies of it for any condition.1

Its safety in people, how it is absorbed, and whether it can trigger immune reactions.1

What is in products sold under the name: FDA notes that the free-base and acetate forms are distinct substances and that inconsistent naming is a safety risk.1

Whether FDA’s rulemaking will add KPV to the 503A list, and how long the October 2026 HHS interim policy will remain in place, remained unresolved in the sources reviewed through November 14, 2026.1,5,6

Sources for this version

  1. 1
    FDA briefing document for KPV ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  2. 2
    July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  3. 3
    Certain bulk drug substances for use in compounding that may present significant safety risks ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  4. 4
    Federal Register notice 2026-07361 · published 2026-04-16 · Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List ↗

    Federal Register via GovInfo · Official source · Source checked August 21, 2026

  5. 5
    Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

    Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  6. 6
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026